This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

AusCann Group Holdings Yönetim

Yönetim kriter kontrolleri 0/4

We currently do not have sufficient information about the CEO.

Anahtar bilgiler

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	no data
CEO sahipliği	n/a
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	2.1yrs

Son yönetim güncellemeleri

Recent updates

We Think AusCann Group Holdings (ASX:AC8) Needs To Drive Business Growth Carefully

Nov 29

CEO

AusCann Group Holdings CEO'su yok ya da onlar hakkında elimizde veri yok.

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christopher Mews	CFO & Director	less than a year	AU$50.00k	0.063% A$ 11.2k
Layton Mills	Executive Officer	less than a year	AU$340.14k	2.84% A$ 501.3k
Margaret Curtis	Head of Research & Development	1.7yrs	AU$250.99k	Veri yok
Susan Park	Joint Company Secretary	6.1yrs	Veri yok	Veri yok

1.0yrs

Ortalama Görev Süresi

Deneyimli Yönetim: AC8's management team is not considered experienced ( 1 years average tenure), which suggests a new team.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Christopher Mews	CFO & Director	2.9yrs	AU$50.00k	0.063% A$ 11.2k
Tod McGrouther	Independent Non-Executive Chairman of the Board	less than a year	AU$48.35k	Veri yok
Robert Clifford	Independent Non-Executive Director	1.6yrs	AU$55.00k	0.14% A$ 25.0k
Krista Bates	Independent Non-Executive Director	2.9yrs	AU$64.93k	0.097% A$ 17.1k
Marc Russo	Chief Medical Advisor & Chairman of Medical Advisory Board	2.1yrs	Veri yok	Veri yok
Peter Gonski	Member of Medical Advisory Board	2.1yrs	Veri yok	Veri yok
Sachin Shetty	Member of Medical Advisory Board	2.1yrs	Veri yok	Veri yok
Peter Georgius	Member of Medical Advisory Board	2.1yrs	Veri yok	Veri yok

2.1yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: AC8's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.

This company listing is no longer active

AusCann Group Holdings Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

AusCann Group Holdings Ltd, Annual General Meeting, Nov 30, 2023

AusCann Group Holdings Limited Announces Executive Changes

AusCann Group Holdings Ltd Announces Resignation of Krista Bates as Non-Executive Director

AusCann Group Holdings Ltd, Annual General Meeting, Nov 30, 2022

AusCann Group Holdings Ltd Announces the Resignation of Layton Mills as Chief Executive Officer

AusCann Group Holdings Ltd Appoints Chris Mews as Chief Financial Officer

Recent updates

AusCann Group Holdings Ltd has withdrawn its Follow-on Equity Offering in the amount of AUD 1 million.

AusCann Group Holdings Ltd has filed a Follow-on Equity Offering in the amount of AUD 1 million.

AusCann Group Holdings Ltd, Annual General Meeting, Nov 30, 2023

AusCann Group Holdings Limited Announces Executive Changes

AusCann Group Holdings Ltd Announces Resignation of Krista Bates as Non-Executive Director

AusCann Group Holdings Ltd, Annual General Meeting, Nov 30, 2022

AusCann Group Holdings Ltd Announces the Resignation of Layton Mills as Chief Executive Officer

Full year 2022 earnings released: AU$0.057 loss per share (vs AU$0.03 loss in FY 2021)

AusCann Group Holdings Ltd Appoints Chris Mews as Chief Financial Officer

High number of new and inexperienced directors

AusCann Receives U.S FDA-CVM Memorandum of Conference for CPAT-01

AusCann Group Holdings Limited Commences Australian Product Registration for Dogs

AusCann Group Holdings Ltd (ASX:AC8) completed the acquisition of CannPal Animal Therapeutics Limited (ASX:CP1) from Merchant Opportunities Fund, managed by Merchant Funds Management Pty Ltd and others.

AusCann Group Holdings Ltd to Report Fiscal Year 2021 Results on Sep 30, 2021

AusCann Group Holdings Limited Announces Executive Changes

Auscann Group Holdings Ltd Appoints Charles Altshuler as Chief Financial Officer, Effective on March 29, 2021

AusCann Group Holdings Ltd to Report Q2, 2021 Results on Jan 29, 2021

AusCann Group Holding Announces Management Changes

New 90-day high: AU$0.24

We Think AusCann Group Holdings (ASX:AC8) Needs To Drive Business Growth Carefully

Fundación Daya entered into an agreement to acquire remaining 50% stake in DayaCann SpA from AusCann Group Holdings Ltd (ASX:AC8) for $1.5 million.

AusCann Group Holdings Limited Establishes Medical Advisory Board of Leading Clinicians in Australia, in the Areas of Pain, Palliative Care and Geriatric Medicine

Full year earnings released - AU$0.022 loss per share

AusCann Group Holdings Ltd Announces Resignation of Quentin Megson as CFO

Full year earnings released - AU$0.022 loss per share

AusCann Group Holdings Ltd Announces Resignation of Marcel Bonn-Miller as Non-Executive Director

AusCann Group Holdings Ltd Appoints Nick Woolf as Chief Executive Officer

AusCann Group Holdings Ltd(ASX:AC8) dropped from S&P/ASX All Ordinaries Index

CEO

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi